imeglimin
Roivant signs $600m licensing deal with Poxel
February 13, 2018Manufacturing and Production, Sales and Marketing Poxel, Roivant, diabetes, imeglimin, pharma
Roivant Sciences has announced that it has entered into a licensing partnership with Poxel to develop and commercialise the latter’s …
Latest content
Recruitment experts hired in search for new CGT Catapult chief
November 14, 2026
Envirogen secures place on NHS Scotland reverse osmosis framework
November 13, 2026
